 | • レポートコード：B-MOR-05516 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥569,800 (USD3,850) | ▷ お問い合わせ |
| Team User（7名様用） | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Corporate User | ￥1,221,000 (USD8,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
The Asia-Pacific over the counter (OTC) drugs market is expected to witness a CAGR of 6.2% during the forecast period, 2018-2023. North America currently holds the largest share in the market, due to the increasing expenditure in healthcare.
Inclination of Pharmaceutical Companies to Switch from Rx to OTC Drug
The switch from Rx to OTC treatment by the pharmaceutical companies, have expanded significantly. And this has resulted in a huge capital savings for the global healthcare system. By this switch, companies are able to brand their products and increase their sales across the world. The lack of regulations or the lack of enforcement of regulations, in developing nations, has boosted the OTC market. This has created a huge opportunity for manufacturers of both Rx and OTC drugs, allowing them to take the advantage of increasing sales force across the OTC product portfolio. Many big firms are coming together to benefit from this promising segment. Recently, a consumer health joint venture of GlaxoSmithKline and Novartis, and Bayer’s USD 14.2 billion acquisition of Merck are indications of the objectives of big companies to exploit the OTC market.
The other factors include, product innovation, high penetration in emerging markets, immense cost savings, and the favorable regulatory framework.
Incorrect Self Diagnosis
The consumers usually prefer to avoid doctor’s visit to save money, and prefer the OTC drugs over prescription medication. For a range of illnesses, 8 in 10 consumers use OTC medicines to get relief from their symptoms without having to see a healthcare professional. Although there is a huge demand for self-medication/OTC medication, there are a few issues that are hindering the growth of the OTC drugs. Some of the consumers are unaware or cannot diagnose the symptoms on their own. Hence it is always recommended that a patient should visit a physician to get the right diagnosis for the symptoms. The incorrect self-diagnosis in using the OTC drugs may have serious health issues, which leads to the damage of consumer’s health. This is a factor of hampering the growth of the OTC drugs market.
The other restraining factors also include, probability of substance abuse and the lack of awareness among the rural regions.
Asia-Pacific Expected to Dominate the Market in the Future
Asia-Pacific is expected to dominate the market due to the increasing access through new channels, players keen to promote self-medication, and key players building strong brand existence. China is predicted to be one of the largest OTC drugs markets by 2021 and the growth is fueled by factors, such as self-medication by patients. After Asia-Pacific, Europe is another lucrative region in the global OTC drugs market. The demand is huge and widespread in this region. Countries, such as France and Germany, in Europe, rank among the top five market places in the world.
Key Developments of the Market
• February 2017: Sanofi announced that the US Food & Drug Administration (FDA) has approved Xyzal Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies.
• February 2017: Sanofi agreed to sell some over-the-counter (OTC) products to Ipsen SA.
Major Players: JOHNSON & JOHNSON, NOVARTIS AG, BAYER AG, SANOFI, PFIZER, GLAXOSMITHKLINE PLC, BOEHRINGER INGELHEIM, PGT HEALTHCARE, AND TAKEDA PHARMACEUTICAL COMPANY, amongst others
Reasons to Purchase the Report
• Current and future market outlook for the over-the-counter (OTC) drugs, in the developed and emerging markets
• Analyze various perspectives on the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support along with the market estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Product Innovation
6.1.2 High Penetration in Emerging Markets
6.1.3 Immense Cost Savings
6.1.4 Favorable Regulatory Framework
6.1.5 Inclination of Pharmaceutical Companies to Switch from Rx to OTC Drugs
6.2 Market Restraints
6.2.1 Lack of Awareness among the Rural Regions
6.2.2 Incorrect Self-diagnosis
6.3 Opportunities
6.4 Key challenges
7. Market Segmentation
7.1 By Product
7.1.1 Cough, Cold, and Flu Products
7.1.2 Analgesics
7.1.3 Dermatology Products
7.1.4 Gastrointestinal Products
7.1.5 Vitamins, Minerals, and Supplements (VMS)
7.1.6 Weight Loss/Dietary products
7.1.7 Ophthalmic Products
7.1.8 Smoking Cession Aids
7.1.9 Anti-Allergy Drugs
7.1.10 Sleep Aids
7.1.11 Others
7.2 By Distribution Channel
7.2.1 Hospital Pharmacies
7.2.2 Retail Pharmacies
7.2.3 Convenience Stores
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 New Zealand
7.3.3.6 South Korea
7.3.3.7 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Johnson & Johnson
9.2 Novartis AG
9.3 Bayer AG
9.4 Sanofi
9.5 Pfizer
9.6 GlaxoSmithKline PLC
9.7 Boehringer Ingelheim
9.8 PGT Healthcare
9.9 Takeda Pharmaceutical Company
9.10 List is not Exhaustive
10. Future of the Market